trophon2®: confidence without compromise

In Australia, patients will suffer from an estimated 165,000 healthcare-associated infections (HAIs) each year.¹ An extensive list of pathogens have been implicated in HAIs. High-level disinfection (HLD) of medical devices, including ultrasound probes, is an essential part of the fight against the wide range of pathogens that cause HAIs.

Developed by Australian infection prevention company Nanosonics, trophon technology has revolutionised high-level disinfection practice around the world with reliable efficacy, safety and reproducibility. The trophon2 device is the latest addition to the trophon family. It has an enhanced user experience and offers health professionals the confidence of the broadest microbial efficacy, plus digital traceability and consistent protection for every patient, every time.

The broadest microbial efficacy

The trophon device goes beyond mandatory requirements and delivers microbial efficacy against the broadest range of clinically relevant pathogens, compared with UV-C systems and ClO₂ wipes.² Nanosonics has conducted extensive testing with the trophon device, demonstrating proven efficacy against multi-drug resistant bacteria like MRSA, sexually transmitted pathogens like HPV, and Clostridium difficile spores.

The trophon device outperforms other methods of disinfection that have been tested in similar clinical settings, with low-level disinfection (LLD) wipes failing to systematically remove bacterial contamination from patient-used ultrasound probes.³ UV-C disinfection also failed to remove bacterial contamination in a clinical setting, with no significant difference in performance to LLD wipes.⁴

Redefining chemistry for confidence

Ultrasound probes contain grooves, crevices and imperfections that can house pathogens. These areas must be disinfected to the same extent as smooth surfaces, but may be missed by some HLD technologies. UV-C light travels in a straight line and must have a direct path to an object to disinfect it, meaning pathogens in crevices or shadowed areas may be missed.⁵

trophon technology has redefined chemistry for HLD of ultrasound probes with its proprietary hydrogen peroxide disinfectant, which is ‘sonically-activated’ to create a very fine mist. This mist generates free radicals that are able to reach hard-to-disinfect shadowed areas of the probe.

Each trophon2 cycle consumes only a small amount of hydrogen peroxide (approximately 2 milliliters), which is broken down at cycle end to the environmentally friendly by-products of water and oxygen. Staff operating the trophon2 device do not handle the hydrogen peroxide, which is sealed in a disinfectant cartridge and emptied automatically once inserted into the device. The trophon2 device does not expose staff to harmful, toxic vapours.

Digitised traceability has never been easier

Australian and New Zealand AS/NZS standards require traceability for HLD of semi-critical and critical medical devices, and state that health service organisations should be working towards implementing digital systems.⁶ Nanosonics AuditPro™ provides facilities with the opportunity to further improve and standardise infection control compliance across all ultrasound procedures. Now, with the new AuditPro digital logbook, trophon2 cycle data is automatically linked to patient procedure ID across every high-level disinfection cycle. The digital logbook eliminates the need for paper-based manual disinfection tracking, reducing human error and administrative burden and saving valuable time.

Australian made with local support

Nanosonics is a trusted partner in infection prevention, offering world-leading technology with local manufacturing, R&D and support. trophon devices are manufactured in Australia and supported by a local team offering first-class customer and technical services.

Contact Nanosonics today to learn more about trophon technology. || Phone 1800 060 244

<sup>1. Mitchell BG et al. Infect Dis Health 2017;22(3):117—128.
2. Nanosonics internal test data & Vickery K et al. J Infect Public Health 2014;7(2):153—160.
3. Buescher DL et al. Ultrasound Obstet Gynecol 2016; 47(5):646-651.
4. Schmitz J et al. Ultraschall in Med 2019; doi: 2010.1055/a-0874-1971.
5. Kowalski W et al. J Microbiol Methods 2022;200:106541.
6. Standards Australia (AS) and Standards New Zealand (NZS). AS NZS 4187 2014.</sup>

_{The trophon family includes both trophon EPR and trophon2 devices which share the same core technology of ‘sonically-activated’ hydrogen peroxide.}

_{Nanosonics, AuditPro and trophon are trademarks of Nanosonics Limited.}